261 related articles for article (PubMed ID: 11831366)
1. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
Shinde UA; Mehta AA; Goyal RK
Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
[TBL] [Abstract][Full Text] [Related]
2. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
DabroĊ W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
3. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
Yao J; Battell ML; McNeill JH
Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
[TBL] [Abstract][Full Text] [Related]
5. The effects of vanadium treatment on bone in diabetic and non-diabetic rats.
Facchini DM; Yuen VG; Battell ML; McNeill JH; Grynpas MD
Bone; 2006 Mar; 38(3):368-77. PubMed ID: 16256449
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
7. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats.
Yuen VG; Pederson RA; Dai S; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1996 Sep; 74(9):1001-9. PubMed ID: 8960391
[TBL] [Abstract][Full Text] [Related]
8. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of different rat models with co-existing diabetes-mellitus and hypertension.
Hakim ZS; Goyal RK
Indian J Physiol Pharmacol; 2000 Apr; 44(2):125-35. PubMed ID: 10846625
[TBL] [Abstract][Full Text] [Related]
10. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
11. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
12. Effect of vanadium on insulin sensitivity and appetite.
Wang J; Yuen VG; McNeill JH
Metabolism; 2001 Jun; 50(6):667-73. PubMed ID: 11398143
[TBL] [Abstract][Full Text] [Related]
13. Anti-diabetic effects of vanadium(III, IV, V)-chlorodipicolinate complexes in streptozotocin-induced diabetic rats.
Li M; Ding W; Smee JJ; Baruah B; Willsky GR; Crans DC
Biometals; 2009 Dec; 22(6):895-905. PubMed ID: 19404749
[TBL] [Abstract][Full Text] [Related]
14. Lack of in vivo effect of vanadium on GLUT4 translocation in white adipose tissue of streptozotocin-diabetic rats.
Cam MC; Brownsey RW; Rodrigues B; McNeill JH
Metabolism; 2001 Jun; 50(6):674-80. PubMed ID: 11398144
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
16. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
Yuen VG; Orvig C; McNeill JH
Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic treatment with losartan on streptozotocin induced diabetic rats.
Murali B; Goyal RK
Indian J Exp Biol; 2002 Jan; 40(1):31-4. PubMed ID: 12561964
[TBL] [Abstract][Full Text] [Related]
19. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
20. Studies on hypoglycaemic effects of polyherbal preparation in streptozotocin-induced diabetic male albino rats.
Ismail Khan A; Yuvaraj S; Suthagar E; Parthasarathy C; Balasubramanian K
Hum Exp Toxicol; 2009 Nov; 28(11):679-87. PubMed ID: 19755436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
